Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori Infection

Clinical Gastroenterology and Hepatology

Volumn 8, Issue 1, 2010, Pages

  Wu, Deng Chyang ^a,b,c   Hsu, Ping I ^d   Wu, Jeng Yih ^a,b   Opekun, Antone R ^e   Kuo, Chao Hung ^b,f   Wu, I Chen ^a   Wang, Sophie S W ^a   Chen, Angela ^c   Hung, Wen Chun ^c   Graham, David Y ^e  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; TETRACYCLINE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENDOSCOPY; FATIGUE; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ANTRUM; STOMACH BIOPSY; TAIWAN; TASTE; TREATMENT DURATION; UREA BREATH TEST; VOMITING;

EID: 72049093198     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.09.030     Document Type: Article

References (41)

1. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA 272 (1994) 65-69
2. Teh B.H., Lin J.T., Pan W.H., et al. Seroprevalence and associated risk factors of Helicobacter pylori infection in Taiwan. Anticancer Res 14 (1994) 1389-1392
3. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56 (2007) 772-781
4. Bytzer P., and O'Morain C. Treatment of Helicobacter pylori. Helicobacter 10 Suppl 1 (2005) 40-46
5. Vakil N., and Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 133 (2007) 985-1001
6. Yamaoka Y., Graham D.Y., and Lu H. Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective?. US Gastroenterology 4 (2008) 65-67
7. Huang A.H., Sheu B.S., Yang H.B., et al. Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy. J Formos Med Assoc 99 (2000) 704-709
8. Zanten S.J., Bradette M., Farley A., et al. The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. Aliment Pharmacol Ther 13 (1999) 289-295
9. Sheu B.S., Wu J.J., Lo C.Y., et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 16 (2002) 1669-1675
10. Bazzoli F., Pozzato P., and Rokkas T. Helicobacter pylori: the challenge in therapy. Helicobacter 7 Suppl 1 (2002) 43-49
11. Georgopoulos S.D., Ladas S.D., Karatapanis S., et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther 16 (2002) 569-575
12. Peitz U., Sulliga M., Wolle K., et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. Aliment Pharmacol Ther 16 (2002) 315-324
13. Vakil N., Lanza F., Schwartz H., et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 20 (2004) 99-107
14. Fuccio L., Minardi M.E., Zagari R.M., et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 147 (2007) 553-562
15. Zagari R.M., Bianchi-Porro G., Fiocca R., et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 56 (2007) 475-479
16. Graham D.Y., Lu H., and Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 12 (2007) 275-278
17. Fischbach L., and Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26 (2007) 343-357
18. Zullo A., Rinaldi V., Winn S., et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 14 (2000) 715-718
19. Jafri N.S., Hornung C.A., and Howden C.W. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 148 (2008) 923-931
20. Vaira D., Zullo A., Vakil N., et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 146 (2007) 556-563
21. Sanchez-Delgado J., Calvet X., Bujanda L., et al. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 103 (2008) 2220-2223
22. Treiber G., Ammon S., Schneider E., et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 3 (1998) 54-58
23. Okada M., Oki K., Shirotani T., et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 33 (1998) 640-645
24. Essa A.S., Kramer J.R., Graham D.Y., et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 14 (2009) 109-118
25. Hu C.T., Wu C.C., Lin C.Y., et al. Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan. J Gastroenterol Hepatol 22 (2007) 720-723
26. Poon S.K., Lai C.H., Chang C.S., et al. Prevalence of antimicrobial resistance in Helicobacter pylori isolates in Taiwan in relation to consumption of antimicrobial agents. Int J Antimicrob Agents 34 (2009) 162-165
27. Chang W.L., Sheu B.S., Cheng H.C., et al. Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 24 (2009) 1230-1235
28. Kuo C.H., Hu H.M., Kuo F.C., et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial. J Antimicrob Chemother 63 (2009) 1017-1024
29. Wu D.C., Hsu P.I., Chen A., et al. Randomized comparison of two rescue therapies for Helicobacter pylori infection. Eur J Clin Invest 36 (2006) 803-809
30. Wu I.C., Ke H.L., Lo Y.C., et al. Evaluation of a newly developed office-based stool test for detecting Helicobacter pylori: an extensive pilot study. Hepatogastroenterology 50 (2003) 1761-1765
31. Hsu P.I., Hwang I.R., Cittelly D., et al. Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island. Am J Gastroenterol 97 (2002) 2231-2238
32. Alarcon T., Domingo D., and Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 12 (1999) 19-26
33. Graham D.Y. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 7 (2009) 145-148
34. Okada M., Nishimura H., Kawashima M., et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 13 (1999) 769-774
35. Treiber G., Wittig J., Ammon S., et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 162 (2002) 153-160
36. Scott D., Weeks D., Melchers K., et al. The life and death of Helicobacter pylori. Gut 43 Suppl 1 (1998) S56-S60
37. Graham D.Y., and Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 331
38. Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 370 (2007) 1010-1012
39. Graham D.Y., Lu H., and Yamaoka Y. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 68 (2008) 725-736
40. Suzuki T., Matsuo K., Ito H., et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med 119 (2006) 217-224
41. Broutet N., Tchamgoue S., Pereira E., et al. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 17 (2003) 99-109